Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives

Progress in Retinal and Eye Research

Volumn 63, Issue , 2018, Pages 107-131

  Dias, Marina França ^a,b   Joo, Kwangsic ^c   Kemp, Jessica A ^b   Fialho, Silvia Ligório ^d   da Silva Cunha, Armando ^a   Woo, Se Joon ^b,c   Kwon, Young Jik ^b,e  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Seoul National University Bundang Hospital   (South Korea)

^d Ezequiel Dias Foundation   (Brazil)

^e University of California at Irvine   (United States)

Author keywords

Gene therapy; Molecular genetics; Retinitis pigmentosa

Indexed keywords

ACETAZOLAMIDE; ADENOVIRUS VECTOR; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BEVACIZUMAB; CARBONATE DEHYDRATASE INHIBITOR; DOCOSAHEXAENOIC ACID; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; RANIBIZUMAB; RETINOL; RHODOPSIN; UNOPROSTONE ISOPROPYL ESTER; VIRUS VECTOR; VORETIGENE NEPARVOVEC; XANTHOPHYLL;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BASIC RESEARCH; CELL TRANSPLANTATION; CLINICAL FEATURE; CRISPR-CAS9 SYSTEM; GENE EDITING; GENE MUTATION; GENE TARGETING; GENE THERAPY; HUMAN; INDUCED PLURIPOTENT STEM CELL; LEBER CONGENITAL AMAUROSIS; MOLECULAR GENETICS; NEUROPROTECTION; NONHUMAN; OPTOGENETICS; PHOTORECEPTOR; PHOTOTRANSDUCTION; PRIORITY JOURNAL; RETINA DYSTROPHY; RETINA MACULA CYSTOID EDEMA; RETINITIS PIGMENTOSA; REVIEW; CLINICAL STUDY; GENETICS; MEDICAL RESEARCH; MOLECULAR BIOLOGY; PROCEDURES;

BIOMEDICAL RESEARCH; CLINICAL STUDIES AS TOPIC; GENETIC THERAPY; HUMANS; MOLECULAR BIOLOGY; RETINITIS PIGMENTOSA;

EID: 85032924613     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2017.10.004     Document Type: Review

References (270)

1. Adackapara, C.A., Sunness, J.S., Dibernardo, C.W., Melia, B.M., Dagnelie, G., Prevalence of cystoid macular edema and stability in oct retinal thickness in eyes with retinitis pigmentosa during a 48-week lutein trial. Retina 28 (2008), 103–110.
2. Adams, N.A., Awadein, A., Toma, H.S., The retinal ciliopathies. Ophthalmic Genet. 28 (2007), 113–125.
3. Ahn, S.J., Kim, K.E., Woo, S.J., Park, K.H., The effect of an intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa: a case report and literature review. Ophthalmic Surg. lasers imaging retina 45 (2014), 160–164.
4. Ait-Ali, N., Fridlich, R., Millet-Puel, G., Clerin, E., Delalande, F., Jaillard, C., Blond, F., Perrocheau, L., Reichman, S., Byrne, L.C., Olivier-Bandini, A., Bellalou, J., Moyse, E., Bouillaud, F., Nicol, X., Dalkara, D., van Dorsselaer, A., Sahel, J.A., Leveillard, T., Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis. Cell 161 (2015), 817–832.
5. Aleman, T.S., Duncan, J.L., Bieber, M.L., de Castro, E., Marks, D.A., Gardner, L.M., Steinberg, J.D., Cideciyan, A.V., Maguire, M.G., Jacobson, S.G., Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Invest Ophthalmol. Vis. Sci. 42 (2001), 1873–1881.
6. Ali, R.R., Sarra, G.M., Stephens, C., Alwis, M.D., Bainbridge, J.W., Munro, P.M., Fauser, S., Reichel, M.B., Kinnon, C., Hunt, D.M., Bhattacharya, S.S., Thrasher, A.J., Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat. Genet. 25 (2000), 306–310.
7. Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L.H., Wilson, J.M., Marigo, V., Surace, E.M., Auricchio, A., Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J. Virol. 81 (2007), 11372–11380.
8. Artunay, O., Yuzbasioglu, E., Rasier, R., Sengul, A., Bahcecioglu, H., Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa. J. Ocul. Pharmacol. Ther. 25 (2009), 545–550.
9. Assawachananont, J., Mandai, M., Okamoto, S., Yamada, C., Eiraku, M., Yonemura, S., Sasai, Y., Takahashi, M., Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice. Stem Cell Rep. 2 (2014), 662–674.
10. Athanasiou, D., Aguila, M., Bevilacqua, D., Novoselov, S.S., Parfitt, D.A., Cheetham, M.E., The cell stress machinery and retinal degeneration. FEBS Lett. 587 (2013), 2008–2017.
11. Auricchio, A., Kobinger, G., Anand, V., Hildinger, M., O'Connor, E., Maguire, A.M., Wilson, J.M., Bennett, J., Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum. Mol. Genet. 10 (2001), 3075–3081.
12. Ayton, L.N., Blamey, P.J., Guymer, R.H., Luu, C.D., Nayagam, D.A., Sinclair, N.C., Shivdasani, M.N., Yeoh, J., McCombe, M.F., Briggs, R.J., Opie, N.L., Villalobos, J., Dimitrov, P.N., Varsamidis, M., Petoe, M.A., McCarthy, C.D., Walker, J.G., Barnes, N., Burkitt, A.N., Williams, C.E., Shepherd, R.K., Allen, P.J., Bionic Vision Australia Research, C. First-in-human trial of a novel suprachoroidal retinal prosthesis. PLoS One, 9, 2014, e115239.
13. Bainbridge, J.W., Mehat, M.S., Sundaram, V., Robbie, S.J., Barker, S.E., Ripamonti, C., Georgiadis, A., Mowat, F.M., Beattie, S.G., Gardner, P.J., Feathers, K.L., Luong, V.A., Yzer, S., Balaggan, K., Viswanathan, A., de Ravel, T.J., Casteels, I., Holder, G.E., Tyler, N., Fitzke, F.W., Weleber, R.G., Nardini, M., Moore, A.T., Thompson, D.A., Petersen-Jones, S.M., Michaelides, M., van den Born, L.I., Stockman, A., Smith, A.J., Rubin, G., Ali, R.R., Long-term effect of gene therapy on Leber's congenital amaurosis. N. Engl. J. Med. 372 (2015), 1887–1897.
14. Bainbridge, J.W., Smith, A.J., Barker, S.S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G.E., Stockman, A., Tyler, N., Petersen-Jones, S., Bhattacharya, S.S., Thrasher, A.J., Fitzke, F.W., Carter, B.J., Rubin, G.S., Moore, A.T., Ali, R.R., Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008), 2231–2239.
15. Bakondi, B., Lv, W., Lu, B., Jones, M.K., Tsai, Y., Kim, K.J., Levy, R., Akhtar, A.A., Breunig, J.J., Svendsen, C.N., Wang, S., In vivo CRISPR/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa. Mol. Ther. 24 (2016), 556–563.
16. Bassuk, A.G., Zheng, A., Li, Y., Tsang, S.H., Mahajan, V.B., Precision medicine: genetic repair of retinitis pigmentosa in patient-derived stem cells. Sci. Rep., 6, 2016, 19969.
17. Becirovic, E., Bohm, S., Nguyen, O.N., Riedmayr, L.M., Koch, M.A., Schulze, E., Kohl, S., Borsch, O., Santos-Ferreira, T., Ader, M., Michalakis, S., Biel, M., In vivo analysis of disease-associated point mutations unveils profound differences in mRNA splicing of Peripherin-2 in rod and cone photoreceptors. PLoS Genet., 12, 2016, e1005811.
18. Beltran, W.A., Cideciyan, A.V., Iwabe, S., Swider, M., Kosyk, M.S., McDaid, K., Martynyuk, I., Ying, G.S., Shaffer, J., Deng, W.T., Boye, S.L., Lewin, A.S., Hauswirth, W.W., Jacobson, S.G., Aguirre, G.D., Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E5844–E5853.
19. Bennett, J., Wellman, J., Marshall, K.A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O.U., Chung, D.C., Sun, J., Wright, J.F., Cross, D.R., Aravand, P., Cyckowski, L.L., Bennicelli, J.L., Mingozzi, F., Auricchio, A., Pierce, E.A., Ruggiero, J., Leroy, B.P., Simonelli, F., High, K.A., Maguire, A.M., Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 388 (2016), 661–672.
20. Bennicelli, J., Wright, J.F., Komaromy, A., Jacobs, J.B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T.S., Wei, Z., Qu, G., Zhou, S., Zeiss, C., Arruda, V.R., Acland, G.M., Dell'Osso, L.F., High, K.A., Maguire, A.M., Bennett, J., Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol. Ther. 16 (2008), 458–465.
21. Berger, W., Kloeckener-Gruissem, B., Neidhardt, J., The molecular basis of human retinal and vitreoretinal diseases. Prog. Retin Eye Res. 29 (2010), 335–375.
22. Berson, E.L., Rosner, B., Sandberg, M.A., Hayes, K.C., Nicholson, B.W., Weigel-DiFranco, C., Willett, W., A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch. Ophthalmol. 111 (1993), 761–772.
23. Berson, E.L., Rosner, B., Sandberg, M.A., Weigel-DiFranco, C., Brockhurst, R.J., Hayes, K.C., Johnson, E.J., Anderson, E.J., Johnson, C.A., Gaudio, A.R., Willett, W.C., Schaefer, E.J., Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch. Ophthalmol. 128 (2010), 403–411.
24. Berson, E.L., Rosner, B., Sandberg, M.A., Weigel-DiFranco, C., Moser, A., Brockhurst, R.J., Hayes, K.C., Johnson, C.A., Anderson, E.J., Gaudio, A.R., Willett, W.C., Schaefer, E.J., Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch. Ophthalmol. 122 (2004), 1297–1305.
25. Berson, E.L., Rosner, B., Sandberg, M.A., Weigel-DiFranco, C., Moser, A., Brockhurst, R.J., Hayes, K.C., Johnson, C.A., Anderson, E.J., Gaudio, A.R., Willett, W.C., Schaefer, E.J., Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch. Ophthalmol. 122 (2004), 1306–1314.
26. Berson, E.L., Rosner, B., Weigel-DiFranco, C., Dryja, T.P., Sandberg, M.A., Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Invest Ophthalmol. Vis. Sci. 43 (2002), 3027–3036.
27. Berson, E.L., Sandberg, M.A., Rosner, B., Birch, D.G., Hanson, A.H., Natural course of retinitis pigmentosa over a three-year interval. Am. J. Ophthalmol. 99 (1985), 240–251.
28. Bhalla, S., Joshi, D., Bhullar, S., Kasuga, D., Park, Y., Kay, C.N., Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid. Br. J. Ophthalmol. 97 (2013), 895–899.
29. Birch, D.G., Anderson, J.L., Fish, G.E., Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod dystrophy. Ophthalmology 106 (1999), 258–268.
30. Birch, D.G., Bennett, L.D., Duncan, J.L., Weleber, R.G., Pennesi, M.E., Long-term follow-up of patients with retinitis pigmentosa receiving intraocular ciliary neurotrophic factor implants. Am. J. Ophthalmol. 170 (2016), 10–14.
31. Birch, D.G., Weleber, R.G., Duncan, J.L., Jaffe, G.J., Tao, W., Ciliary neurotrophic factor retinitis pigmentosa study, G. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am. J. Ophthalmol. 156 (2013), 283–292 e281.
32. Boon, C.J., den Hollander, A.I., Hoyng, C.B., Cremers, F.P., Klevering, B.J., Keunen, J.E., The spectrum of retinal dystrophies caused by mutations in the peripherin/RDS gene. Prog. Retin Eye Res. 27 (2008), 213–235.
33. Bourges, J.L., Gautier, S.E., Delie, F., Bejjani, R.A., Jeanny, J.C., Gurny, R., BenEzra, D., Behar-Cohen, F.F., Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol. Vis. Sci. 44 (2003), 3562–3569.
34. Brennan, T.A., Wilson, J.M., The special case of gene therapy pricing. Nat. Biotechnol. 32 (2014), 874–876.
35. Broadgate, S., Yu, J., Downes, S.M., Halford, S., Unravelling the genetics of inherited retinal dystrophies: past, present and future. Prog. Retin Eye Res. 59 (2017), 53–96.
36. Buch, P.K., MacLaren, R.E., Ali, R.R., Neuroprotective gene therapy for the treatment of inherited retinal degeneration. Curr. Gene Ther. 7 (2007), 434–445.
37. Buch, P.K., MacLaren, R.E., Duran, Y., Balaggan, K.S., MacNeil, A., Schlichtenbrede, F.C., Smith, A.J., Ali, R.R., In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration. Mol. Ther. 14 (2006), 700–709.
38. Burnight, E.R., Gupta, M., Wiley, L.A., Anfinson, K.R., Tran, A., Triboulet, R., Hoffmann, J.M., Klaahsen, D.L., Andorf, J.L., Jiao, C., Sohn, E.H., Adur, M.K., Ross, J.W., Mullins, R.F., Daley, G.Q., Schlaeger, T.M., Stone, E.M., Tucker, B.A., Using CRISPR-Cas9 to generate gene-corrected autologous iPSCs for the treatment of inherited retinal degeneration. Mol. Ther. 25 (2017), 1999–2013.
39. Busskamp, V., Duebel, J., Balya, D., Fradot, M., Viney, T.J., Siegert, S., Groner, A.C., Cabuy, E., Forster, V., Seeliger, M., Biel, M., Humphries, P., Paques, M., Mohand-Said, S., Trono, D., Deisseroth, K., Sahel, J.A., Picaud, S., Roska, B., Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science 329 (2010), 413–417.
40. Butterwick, A., Huie, P., Jones, B.W., Marc, R.E., Marmor, M., Palanker, D., Effect of shape and coating of a subretinal prosthesis on its integration with the retina. Exp. Eye Res. 88 (2009), 22–29.
41. Byrne, A.M., Roche, S.L., Ruiz-Lopez, A.M., Jackson, A.C., Cotter, T.G., The synthetic progestin norgestrel acts to increase LIF levels in the rd10 mouse model of retinitis pigmentosa. Mol. Vis. 22 (2016), 264–274.
42. Byrne, L.C., Dalkara, D., Luna, G., Fisher, S.K., Clerin, E., Sahel, J.A., Leveillard, T., Flannery, J.G., Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration. J. Clin. Invest 125 (2015), 105–116.
43. Cai, X., Conley, S.M., Naash, M.I., RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet. 30 (2009), 57–62.
44. Cai, X., Conley, S.M., Nash, Z., Fliesler, S.J., Cooper, M.J., Naash, M.I., Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J. 24 (2010), 1178–1191.
45. Caspi, A., Dorn, J.D., McClure, K.H., Humayun, M.S., Greenberg, R.J., McMahon, M.J., Feasibility study of a retinal prosthesis: spatial vision with a 16-electrode implant. Arch. Ophthalmol. 127 (2009), 398–401.
46. Cehajic-Kapetanovic, J., Eleftheriou, C., Allen, A.E., Milosavljevic, N., Pienaar, A., Bedford, R., Davis, K.E., Bishop, P.N., Lucas, R.J., Restoration of vision with ectopic expression of human rod opsin. Curr. Biol. 25 (2015), 2111–2122.
47. Chadderton, N., Millington-Ward, S., Palfi, A., O'Reilly, M., Tuohy, G., Humphries, M.M., Li, T., Humphries, P., Kenna, P.F., Farrar, G.J., Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol. Ther. 17 (2009), 593–599.
48. Chan, P., Stolz, J., Kohl, S., Chiang, W.C., Lin, J.H., Endoplasmic reticulum stress in human photoreceptor diseases. Brain Res. 1648 (2016), 538–541.
49. Chang, G.Q., Hao, Y., Wong, F., Apoptosis: final common pathway of photoreceptor death in rd, rds, and rhodopsin mutant mice. Neuron 11 (1993), 595–605.
50. Chen, G., Huang, L.D., Jiang, Y.M., Manji, H.K., The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72 (1999), 1327–1330.
51. Chen, P.S., Wang, C.C., Bortner, C.D., Peng, G.S., Wu, X., Pang, H., Lu, R.B., Gean, P.W., Chuang, D.M., Hong, J.S., Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 149 (2007), 203–212.
52. Chen, Y., Moiseyev, G., Takahashi, Y., Ma, J.X., RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65-/- mice. Invest Ophthalmol. Vis. Sci. 47 (2006), 1177–1184.
53. Chow, A.Y., Chow, V.Y., Packo, K.H., Pollack, J.S., Peyman, G.A., Schuchard, R., The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa. Arch. Ophthalmol. 122 (2004), 460–469.
54. Cideciyan, A.V., Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog. Retin Eye Res. 29 (2010), 398–427.
55. Cideciyan, A.V., Hauswirth, W.W., Aleman, T.S., Kaushal, S., Schwartz, S.B., Boye, S.L., Windsor, E.A., Conlon, T.J., Sumaroka, A., Pang, J.J., Roman, A.J., Byrne, B.J., Jacobson, S.G., Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum. Gene Ther. 20 (2009), 999–1004.
56. Clemson, C.M., Tzekov, R., Krebs, M., Checchi, J.M., Bigelow, C., Kaushal, S., Therapeutic potential of valproic acid for retinitis pigmentosa. Br. J. Ophthalmol. 95 (2011), 89–93.
57. Coco, M., Han, S.W., Sallum, J.M., [Gene therapy for inherited retinal dystrophies]. Arq. Bras. Oftalmol. 72 (2009), 560–566.
58. Cohen, A.I., Some cytological and initial biochemical observations on photoreceptors in retinas of rds mice. Invest Ophthalmol. Vis. Sci. 24 (1983), 832–843.
59. Conlon, T.J., Deng, W.T., Erger, K., Cossette, T., Pang, J.J., Ryals, R., Clement, N., Cleaver, B., McDoom, I., Boye, S.E., Peden, M.C., Sherwood, M.B., Abernathy, C.R., Alkuraya, F.S., Boye, S.L., Hauswirth, W.W., Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Hum. Gene Ther. Clin. Dev. 24 (2013), 23–28.
60. Cox, D.B., Platt, R.J., Zhang, F., Therapeutic genome editing: prospects and challenges. Nat. Med. 21 (2015), 121–131.
61. Cox, S.N., Hay, E., Bird, A.C., Treatment of chronic macular edema with acetazolamide. Arch. Ophthalmol. 106 (1988), 1190–1195.
62. Cuenca, N., Fernandez-Sanchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., Pinilla, I., Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Prog. Retin Eye Res. 43 (2014), 17–75.
63. Dalkara, D., Byrne, L.C., Klimczak, R.R., Visel, M., Yin, L., Merigan, W.H., Flannery, J.G., Schaffer, D.V., In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med., 5, 2013, 189 ra176.
64. Dalkara, D., Goureau, O., Marazova, K., Sahel, J.A., Let there Be light: gene and cell therapy for blindness. Hum. Gene Ther. 27 (2016), 134–147.
65. Dalkara, D., Kolstad, K.D., Caporale, N., Visel, M., Klimczak, R.R., Schaffer, D.V., Flannery, J.G., Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol. Ther. 17 (2009), 2096–2102.
66. Dalkara, D., Sahel, J.A., Gene therapy for inherited retinal degenerations. C R. Biol. 337 (2014), 185–192.
67. Danciger, M., Blaney, J., Gao, Y.Q., Zhao, D.Y., Heckenlively, J.R., Jacobson, S.G., Farber, D.B., Mutations in the PDE6B gene in autosomal recessive retinitis pigmentosa. Genomics 30 (1995), 1–7.
68. Deery, E.C., Vithana, E.N., Newbold, R.J., Gallon, V.A., Bhattacharya, S.S., Warren, M.J., Hunt, D.M., Wilkie, S.E., Disease mechanism for retinitis pigmentosa (RP11) caused by mutations in the splicing factor gene PRPF31. Hum. Mol. Genet. 11 (2002), 3209–3219.
69. den Hollander, A.I., Roepman, R., Koenekoop, R.K., Cremers, F.P., Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog. Retin Eye Res. 27 (2008), 391–419.
70. Dinculescu, A., Glushakova, L., Min, S.H., Hauswirth, W.W., Adeno-associated virus-vectored gene therapy for retinal disease. Hum. Gene Ther. 16 (2005), 649–663.
71. Doonan, F., O'Driscoll, C., Kenna, P., Cotter, T.G., Enhancing survival of photoreceptor cells in vivo using the synthetic progestin Norgestrel. J. Neurochem. 118 (2011), 915–927.
72. Doroudchi, M.M., Greenberg, K.P., Liu, J., Silka, K.A., Boyden, E.S., Lockridge, J.A., Arman, A.C., Janani, R., Boye, S.E., Boye, S.L., Gordon, G.M., Matteo, B.C., Sampath, A.P., Hauswirth, W.W., Horsager, A., Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol. Ther. 19 (2011), 1220–1229.
73. Drack, A.V., Dumitrescu, A.V., Bhattarai, S., Gratie, D., Stone, E.M., Mullins, R., Sheffield, V.C., TUDCA slows retinal degeneration in two different mouse models of retinitis pigmentosa and prevents obesity in Bardet-Biedl syndrome type 1 mice. Invest Ophthalmol. Vis. Sci. 53 (2012), 100–106.
74. Dragunow, M., Greenwood, J.M., Cameron, R.E., Narayan, P.J., O'Carroll, S.J., Pearson, A.G., Gibbons, H.M., Valproic acid induces caspase 3-mediated apoptosis in microglial cells. Neuroscience 140 (2006), 1149–1156.
75. Duebel, J., Marazova, K., Sahel, J.A., Optogenetics. Curr. Opin. Ophthalmol. 26 (2015), 226–232.
76. Eigeldinger-Berthou, S., Meier, C., Zulliger, R., Lecaude, S., Enzmann, V., Sarra, G.M., Rasagiline interferes with neurodegeneration in the Prph2/rds mouse. Retina 32 (2012), 617–628.
77. Fahim, A.T., Daiger, S.P., Weleber, R.G., Nonsyndromic retinitis pigmentosa overview. Pagon, R.A., Adam, M.P., Ardinger, H.H., Wallace, S.E., Amemiya, A., Bean, L.J.H., Bird, T.D., Ledbetter, N., Mefford, H.C., Smith, R.J.H., Stephens, K., (eds.) GeneReviews(R), Seattle (WA), 1993.
78. Fahim, A.T., Daiger, S.P., Weleber, R.G., Retinitis pigmentosa overview. Pagon, R.A., Adam, M.P., Ardinger, H.H., Wallace, S.E., Amemiya, A., Bean, L.J.H., Bird, T.D., Fong, C.T., Mefford, H.C., Smith, R.J.H., Stephens, K., (eds.) GeneReviews(R), Seattle (WA), 1993.
79. Fernandez-Sanchez, L., Lax, P., Isiegas, C., Ayuso, E., Ruiz, J.M., de la Villa, P., Bosch, F., de la Rosa, E.J., Cuenca, N., Proinsulin slows retinal degeneration and vision loss in the P23H rat model of retinitis pigmentosa. Hum. Gene Ther. 23 (2012), 1290–1300.
80. Ferrari, S., Di Iorio, E., Barbaro, V., Ponzin, D., Sorrentino, F.S., Parmeggiani, F., Retinitis pigmentosa: genes and disease mechanisms. Curr. Genomics 12 (2011), 238–249.
81. Fliesler, S.J., Anderson, R.E., Chemistry and metabolism of lipids in the vertebrate retina. Prog. Lipid Res. 22 (1983), 79–131.
82. Forsythe, E., Beales, P.L., Bardet-Biedl syndrome. Eur. J. Hum. Genet. 21 (2013), 8–13.
83. Fox, D.A., Poblenz, A.T., He, L., Harris, J.B., Medrano, C.J., Pharmacological strategies to block rod photoreceptor apoptosis caused by calcium overload: a mechanistic target-site approach to neuroprotection. Eur. J. Ophthalmol. 13:Suppl 3 (2003), S44–S56.
84. Frasson, M., Sahel, J.A., Fabre, M., Simonutti, M., Dreyfus, H., Picaud, S., Retinitis pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse. Nat. Med. 5 (1999), 1183–1187.
85. Fujikado, T., Kamei, M., Sakaguchi, H., Kanda, H., Morimoto, T., Ikuno, Y., Nishida, K., Kishima, H., Maruo, T., Konoma, K., Ozawa, M., Nishida, K., Testing of semichronically implanted retinal prosthesis by suprachoroidal-transretinal stimulation in patients with retinitis pigmentosa. Invest Ophthalmol. Vis. Sci. 52 (2011), 4726–4733.
86. Gao, J., Cheon, K., Nusinowitz, S., Liu, Q., Bei, D., Atkins, K., Azimi, A., Daiger, S.P., Farber, D.B., Heckenlively, J.R., Pierce, E.A., Sullivan, L.S., Zuo, J., Progressive photoreceptor degeneration, outer segment dysplasia, and rhodopsin mislocalization in mice with targeted disruption of the retinitis pigmentosa-1 (Rp1) gene. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 5698–5703.
87. Glybina, I.V., Kennedy, A., Ashton, P., Abrams, G.W., Iezzi, R., Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide. Invest Ophthalmol. Vis. Sci. 50 (2009), 4847–4857.
88. Gorbatyuk, M.S., Knox, T., LaVail, M.M., Gorbatyuk, O.S., Noorwez, S.M., Hauswirth, W.W., Lin, J.H., Muzyczka, N., Lewin, A.S., Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 5961–5966.
89. Gouras, P., Carr, R.E., Gunkel, R.D., Retinitis pigmentosa in abetalipoproteinemia: effects of vitamin A. Invest Ophthalmol. 10 (1971), 784–793.
90. Grover, S., Apushkin, M.A., Fishman, G.A., Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am. J. Ophthalmol. 141 (2006), 850–858.
91. Grover, S., Fishman, G.A., Anderson, R.J., Alexander, K.R., Derlacki, D.J., Rate of visual field loss in retinitis pigmentosa. Ophthalmology 104 (1997), 460–465.
92. Guadagni, V., Novelli, E., Piano, I., Gargini, C., Strettoi, E., Pharmacological approaches to retinitis pigmentosa: a laboratory perspective. Prog. Retin Eye Res. 48 (2015), 62–81.
93. Hafler, B.P., Comander, J., Weigel DiFranco, C., Place, E.M., Pierce, E.A., Course of ocular function in PRPF31 retinitis pigmentosa. Semin. Ophthalmol. 31 (2016), 49–52.
94. Hajali, M., Fishman, G.A., Anderson, R.J., The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br. J. Ophthalmol. 92 (2008), 1065–1068.
95. Hamel, C., Retinitis pigmentosa. Orphanet J. Rare Dis., 1, 2006, 40.
96. Han, J., Dinculescu, A., Dai, X., Du, W., Smith, W.C., Pang, J., Review: the history and role of naturally occurring mouse models with Pde6b mutations. Mol. Vis. 19 (2013), 2579–2589.
97. Hartong, D.T., Berson, E.L., Dryja, T.P., Retinitis pigmentosa. Lancet 368 (2006), 1795–1809.
98. Harvey, A.R., Hu, Y., Leaver, S.G., Mellough, C.B., Park, K., Verhaagen, J., Plant, G.W., Cui, Q., Gene therapy and transplantation in CNS repair: the visual system. Prog. Retin Eye Res. 25 (2006), 449–489.
99. Harvey, A.R., Kamphuis, W., Eggers, R., Symons, N.A., Blits, B., Niclou, S., Boer, G.J., Verhaagen, J., Intravitreal injection of adeno-associated viral vectors results in the transduction of different types of retinal neurons in neonatal and adult rats: a comparison with lentiviral vectors. Mol. Cell Neurosci. 21 (2002), 141–157.
100. Hauswirth, W.W., Aleman, T.S., Kaushal, S., Cideciyan, A.V., Schwartz, S.B., Wang, L., Conlon, T.J., Boye, S.L., Flotte, T.R., Byrne, B.J., Jacobson, S.G., Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19 (2008), 979–990.
101. Heidenreich, M., Zhang, F., Applications of CRISPR-Cas systems in neuroscience. Nat. Rev. Neurosci. 17 (2016), 36–44.
102. Hims, M.M., Diager, S.P., Inglehearn, C.F., Retinitis pigmentosa: genes, proteins and prospects. Dev. Ophthalmol. 37 (2003), 109–125.
103. Ho, A.C., Humayun, M.S., Dorn, J.D., da Cruz, L., Dagnelie, G., Handa, J., Barale, P.O., Sahel, J.A., Stanga, P.E., Hafezi, F., Safran, A.B., Salzmann, J., Santos, A., Birch, D., Spencer, R., Cideciyan, A.V., de Juan, E., Duncan, J.L., Eliott, D., Fawzi, A., Olmos de Koo, L.C., Brown, G.C., Haller, J.A., Regillo, C.D., Del Priore, L.V., Arditi, A., Geruschat, D.R., Greenberg, R.J., Argus, I.I.S.G., Long-term results from an epiretinal prosthesis to restore Sight to the blind. Ophthalmology 122 (2015), 1547–1554.
104. Hoffman, D.R., Locke, K.G., Wheaton, D.H., Fish, G.E., Spencer, R., Birch, D.G., A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am. J. Ophthalmol. 137 (2004), 704–718.
105. Hong, C.A., Cho, S.K., Edson, J.A., Kim, J., Ingato, D., Pham, B., Chuang, A., Fruman, D.A., Kwon, Y.J., Viral/nonviral chimeric nanoparticles to synergistically suppress leukemia proliferation via simultaneous gene transduction and silencing. ACS Nano 10 (2016), 8705–8714.
106. Humayun, M.S., de Juan, E. Jr., Weiland, J.D., Dagnelie, G., Katona, S., Greenberg, R., Suzuki, S., Pattern electrical stimulation of the human retina. Vis. Res. 39 (1999), 2569–2576.
107. Humayun, M.S., Dorn, J.D., da Cruz, L., Dagnelie, G., Sahel, J.A., Stanga, P.E., Cideciyan, A.V., Duncan, J.L., Eliott, D., Filley, E., Ho, A.C., Santos, A., Safran, A.B., Arditi, A., Del Priore, L.V., Greenberg, R.J., Argus, I.I.S.G., Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology 119 (2012), 779–788.
108. Humayun, M.S., Weiland, J.D., Fujii, G.Y., Greenberg, R., Williamson, R., Little, J., Mech, B., Cimmarusti, V., Van Boemel, G., Dagnelie, G., de Juan, E., Visual perception in a blind subject with a chronic microelectronic retinal prosthesis. Vis. Res. 43 (2003), 2573–2581.
109. Hung, S.S., McCaughey, T., Swann, O., Pebay, A., Hewitt, A.W., Genome engineering in ophthalmology: application of CRISPR/Cas to the treatment of eye disease. Prog. Retin Eye Res. 53 (2016), 1–20.
110. Ikeda, Y., Yoshida, N., Notomi, S., Murakami, Y., Hisatomi, T., Enaida, H., Ishibashi, T., Therapeutic effect of prolonged treatment with topical dorzolamide for cystoid macular oedema in patients with retinitis pigmentosa. Br. J. Ophthalmol. 97 (2013), 1187–1191.
111. Illing, M.E., Rajan, R.S., Bence, N.F., Kopito, R.R., A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem. 277 (2002), 34150–34160.
112. Iraha, S., Hirami, Y., Ota, S., Sunagawa, G.A., Mandai, M., Tanihara, H., Takahashi, M., Kurimoto, Y., Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study. Clin. Ophthalmol. 10 (2016), 1375–1384.
113. Ivanova, E., Hwang, G.S., Pan, Z.H., Troilo, D., Evaluation of AAV-mediated expression of Chop2-GFP in the marmoset retina. Invest Ophthalmol. Vis. Sci. 51 (2010), 5288–5296.
114. Jacobson, S.G., Acland, G.M., Aguirre, G.D., Aleman, T.S., Schwartz, S.B., Cideciyan, A.V., Zeiss, C.J., Komaromy, A.M., Kaushal, S., Roman, A.J., Windsor, E.A., Sumaroka, A., Pearce-Kelling, S.E., Conlon, T.J., Chiodo, V.A., Boye, S.L., Flotte, T.R., Maguire, A.M., Bennett, J., Hauswirth, W.W., Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol. Ther. 13 (2006), 1074–1084.
115. Jacobson, S.G., Cideciyan, A.V., Roman, A.J., Sumaroka, A., Schwartz, S.B., Heon, E., Hauswirth, W.W., Improvement and decline in vision with gene therapy in childhood blindness. N. Engl. J. Med. 372 (2015), 1920–1926.
116. Jayakody, S.A., Gonzalez-Cordero, A., Ali, R.R., Pearson, R.A., Cellular strategies for retinal repair by photoreceptor replacement. Prog. Retin Eye Res. 46 (2015), 31–66.
117. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821.
118. Jo, D.H., Kim, J.H., Kim, J.H., How to overcome retinal neuropathy: the fight against angiogenesis-related blindness. Arch. Pharm. Res. 33 (2010), 1557–1565.
119. Jones, B.W., Pfeiffer, R.L., Ferrell, W.D., Watt, C.B., Marmor, M., Marc, R.E., Retinal remodeling in human retinitis pigmentosa. Exp. Eye Res. 150 (2016), 149–165.
120. Jones, B.W., Watt, C.B., Frederick, J.M., Baehr, W., Chen, C.K., Levine, E.M., Milam, A.H., Lavail, M.M., Marc, R.E., Retinal remodeling triggered by photoreceptor degenerations. J. Comp. Neurol. 464 (2003), 1–16.
121. Jones, M.K., Lu, B., Girman, S., Wang, S., Cell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases. Prog. Retin Eye Res. 58 (2017), 1–27.
122. Kay, C.N., Ryals, R.C., Aslanidi, G.V., Min, S.H., Ruan, Q., Sun, J., Dyka, F.M., Kasuga, D., Ayala, A.E., Van Vliet, K., Agbandje-McKenna, M., Hauswirth, W.W., Boye, S.L., Boye, S.E., Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One, 8, 2013, e62097.
123. Kelly, S.K., Ellersick, W.F., Krishnan, A., Doyle, P., Shire, D.B., Wyatt, J.L., Rizzo, J.F., Redundant safety features in a high-channel-count retinal neurostimulator. IEEE Biomed. Circuits Syst. Conf. 2014 (2014), 216–219.
124. Kennan, A., Aherne, A., Humphries, P., Light in retinitis pigmentosa. Trends Genet. 21 (2005), 103–110.
125. Kim, C., Chung, H., Yu, H.G., Association of p.P347L in the rhodopsin gene with early-onset cystoid macular edema in patients with retinitis pigmentosa. Ophthalmic Genet. 33 (2012), 96–99.
126. Kim, J.E., Intravitreal triamcinolone acetonide for treatment of cystoid macular edema associated with retinitis pigmentosa. Retina 26 (2006), 1094–1096.
127. Kim, Y.J., Joe, S.G., Lee, D.H., Lee, J.Y., Kim, J.G., Yoon, Y.H., Correlations between spectral-domain OCT measurements and visual acuity in cystoid macular edema associated with retinitis pigmentosa. Invest Ophthalmol. Vis. Sci. 54 (2013), 1303–1309.
128. Koch, S., Sothilingam, V., Garcia Garrido, M., Tanimoto, N., Becirovic, E., Koch, F., Seide, C., Beck, S.C., Seeliger, M.W., Biel, M., Muhlfriedel, R., Michalakis, S., Gene therapy restores vision and delays degeneration in the CNGB1(-/-) mouse model of retinitis pigmentosa. Hum. Mol. Genet. 21 (2012), 4486–4496.
129. Koirala, A., Conley, S.M., Naash, M.I., A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium. Biomaterials 34 (2013), 7158–7167.
130. Kolomeyer, A.M., Zarbin, M.A., Trophic factors in the pathogenesis and therapy for retinal degenerative diseases. Surv. Ophthalmol. 59 (2014), 134–165.
131. Kolstad, K.D., Dalkara, D., Guerin, K., Visel, M., Hoffmann, N., Schaffer, D.V., Flannery, J.G., Changes in adeno-associated virus-mediated gene delivery in retinal degeneration. Hum. Gene Ther. 21 (2010), 571–578.
132. Koo, H., Moon, H., Han, H., Na, J.H., Huh, M.S., Park, J.H., Woo, S.J., Park, K.H., Kwon, I.C., Kim, K., Kim, H., The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 33 (2012), 3485–3493.
133. Kumar, A., Midha, N., Gogia, V., Gupta, S., Sehra, S., Chohan, A., Efficacy of oral valproic acid in patients with retinitis pigmentosa. J. Ocul. Pharmacol. Ther. 30 (2014), 580–586.
134. Kuriyan, A.E., Albini, T.A., Townsend, J.H., Rodriguez, M., Pandya, H.K., Leonard, R.E. 2nd, Parrott, M.B., Rosenfeld, P.J., Flynn, H.W. Jr., Goldberg, J.L., Vision loss after intravitreal injection of autologous “stem cells” for AMD. N. Engl. J. Med. 376 (2017), 1047–1053.
135. Lamb, T.D., Evolution of phototransduction, vertebrate photoreceptors and retina. Prog. Retin Eye Res. 36 (2013), 52–119.
136. Lamba, D.A., McUsic, A., Hirata, R.K., Wang, P.R., Russell, D., Reh, T.A., Generation, purification and transplantation of photoreceptors derived from human induced pluripotent stem cells. PLoS One, 5, 2010, e8763.
137. Lebherz, C., Maguire, A., Tang, W., Bennett, J., Wilson, J.M., Novel AAV serotypes for improved ocular gene transfer. J. Gene Med. 10 (2008), 375–382.
138. Lee, H., Lotery, A., Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3. Lancet 390 (2017), 823–824.
139. Lee, J., Ryoo, N.K., Han, H., Hong, H.K., Park, J.Y., Park, S.J., Kim, Y.K., Sim, C., Kim, K., Woo, S.J., Park, K.H., Kim, H., Anti-vegf PolysiRNA polyplex for the treatment of choroidal neovascularization. Mol. Pharm. 13 (2016), 1988–1995.
140. Lee, S.Y., Usui, S., Zafar, A.B., Oveson, B.C., Jo, Y.J., Lu, L., Masoudi, S., Campochiaro, P.A., N-Acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa. J. Cell Physiol. 226 (2011), 1843–1849.
141. Leonard, K.C., Petrin, D., Coupland, S.G., Baker, A.N., Leonard, B.C., LaCasse, E.C., Hauswirth, W.W., Korneluk, R.G., Tsilfidis, C., XIAP protection of photoreceptors in animal models of retinitis pigmentosa. PLoS One, 2, 2007, e314.
142. Leveillard, T., Mohand-Said, S., Lorentz, O., Hicks, D., Fintz, A.C., Clerin, E., Simonutti, M., Forster, V., Cavusoglu, N., Chalmel, F., Dolle, P., Poch, O., Lambrou, G., Sahel, J.A., Identification and characterization of rod-derived cone viability factor. Nat. Genet. 36 (2004), 755–759.
143. Li, Q., Miller, R., Han, P.Y., Pang, J., Dinculescu, A., Chiodo, V., Hauswirth, W.W., Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol. Vis. 14 (2008), 1760–1769.
144. Li, T., Sandberg, M.A., Pawlyk, B.S., Rosner, B., Hayes, K.C., Dryja, T.P., Berson, E.L., Effect of vitamin A supplementation on rhodopsin mutants threonine-17–> methionine and proline-347–> serine in transgenic mice and in cell cultures. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 11933–11938.
145. Li, Y., Tsai, Y.T., Hsu, C.W., Erol, D., Yang, J., Wu, W.H., Davis, R.J., Egli, D., Tsang, S.H., Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. Mol. Med. 18 (2012), 1312–1319.
146. Liang, F.Q., Aleman, T.S., Dejneka, N.S., Dudus, L., Fisher, K.J., Maguire, A.M., Jacobson, S.G., Bennett, J., Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa. Mol. Ther. 4 (2001), 461–472.
147. Lin, B., Koizumi, A., Tanaka, N., Panda, S., Masland, R.H., Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 16009–16014.
148. Linder, B., Hirmer, A., Gal, A., Ruther, K., Bolz, H.J., Winkler, C., Laggerbauer, B., Fischer, U., Identification of a PRPF4 loss-of-function variant that abrogates U4/U6.U5 tri-snRNP integration and is associated with retinitis pigmentosa. PLoS One, 9, 2014, e111754.
149. Lingao, M.D., Ganesh, A., Karthikeyan, A.S., Al Zuhaibi, S., Al-Hosni, A., Al Khayat, A., Capasso, J., Trumler, A.A., Stroh, E., Al Shekaili, H., Cater, J.R., Levin, A.V., Macular cystoid spaces in patients with retinal dystrophy. Ophthalmic Genet. 37 (2016), 377–383.
150. Lipinski, D.M., Barnard, A.R., Singh, M.S., Martin, C., Lee, E.J., Davies, W.I., MacLaren, R.E., CNTF gene therapy Confers lifelong neuroprotection in a mouse model of human retinitis pigmentosa. Mol. Ther. 23 (2015), 1308–1319.
151. Lipinski, D.M., Thake, M., MacLaren, R.E., Clinical applications of retinal gene therapy. Prog. Retin Eye Res. 32 (2013), 22–47.
152. Lotery, A.J., Yang, G.S., Mullins, R.F., Russell, S.R., Schmidt, M., Stone, E.M., Lindbloom, J.D., Chiorini, J.A., Kotin, R.M., Davidson, B.L., Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. Hum. Gene Ther. 14 (2003), 1663–1671.
153. Luo, Y.H., da Cruz, L., The Argus((R)) II retinal prosthesis system. Prog. Retin Eye Res. 50 (2016), 89–107.
154. MacLaren, R.E., Bennett, J., Schwartz, S.D., Gene therapy and stem cell transplantation in retinal disease: the new frontier. Ophthalmology 123 (2016), S98–S106.
155. MacLaren, R.E., Groppe, M., Barnard, A.R., Cottriall, C.L., Tolmachova, T., Seymour, L., Clark, K.R., During, M.J., Cremers, F.P., Black, G.C., Lotery, A.J., Downes, S.M., Webster, A.R., Seabra, M.C., Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383 (2014), 1129–1137.
156. Maguire, A.M., High, K.A., Auricchio, A., Wright, J.F., Pierce, E.A., Testa, F., Mingozzi, F., Bennicelli, J.L., Ying, G.S., Rossi, S., Fulton, A., Marshall, K.A., Banfi, S., Chung, D.C., Morgan, J.I., Hauck, B., Zelenaia, O., Zhu, X., Raffini, L., Coppieters, F., De Baere, E., Shindler, K.S., Volpe, N.J., Surace, E.M., Acerra, C., Lyubarsky, A., Redmond, T.M., Stone, E., Sun, J., McDonnell, J.W., Leroy, B.P., Simonelli, F., Bennett, J., Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374 (2009), 1597–1605.
157. Maguire, A.M., Simonelli, F., Pierce, E.A., Pugh, E.N. Jr., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K.A., Testa, F., Surace, E.M., Rossi, S., Lyubarsky, A., Arruda, V.R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'Osso, L., Hertle, R., Ma, J.X., Redmond, T.M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K.S., Maguire, M.G., Wright, J.F., Volpe, N.J., McDonnell, J.W., Auricchio, A., High, K.A., Bennett, J., Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008), 2240–2248.
158. Mandai, M., Fujii, M., Hashiguchi, T., Sunagawa, G.A., Ito, S., Sun, J., Kaneko, J., Sho, J., Yamada, C., Takahashi, M., iPSC-derived retina transplants improve vision in rd1 end-stage retinal-degeneration mice. Stem Cell Rep. 8 (2017), 69–83.
159. Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., Terada, M., Nomiya, Y., Tanishima, S., Nakamura, M., Kamao, H., Sugita, S., Onishi, A., Ito, T., Fujita, K., Kawamata, S., Go, M.J., Shinohara, C., Hata, K.I., Sawada, M., Yamamoto, M., Ohta, S., Ohara, Y., Yoshida, K., Kuwahara, J., Kitano, Y., Amano, N., Umekage, M., Kitaoka, F., Tanaka, A., Okada, C., Takasu, N., Ogawa, S., Yamanaka, S., Takahashi, M., Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 376 (2017), 1038–1046.
160. Mansour, A.M., Sheheitli, H., Kucukerdonmez, C., Sisk, R.A., Moura, R., Moschos, M.M., Lima, L.H., Al-Shaar, L., Arevalo, J.F., Maia, M., Foster, R.E., Kayikcioglu, O., Kozak, I., Kurup, S., Zegarra, H., Gallego-Pinazo, R., Hamam, R.N., Bejjani, R.A., Cinar, E., Erakgun, E.T., Kimura, A., Teixeira, A., Intravitreal dexamethasone implant in retinitis pigmentosa-related cystoid macular edema. Retina, 2017 [E-pub ahead of print].
161. Mantopoulos, D., Murakami, Y., Comander, J., Thanos, A., Roh, M., Miller, J.W., Vavvas, D.G., Tauroursodeoxycholic acid (TUDCA) protects photoreceptors from cell death after experimental retinal detachment. PLoS One, 6, 2011, e24245.
162. Mao, H., James, T. Jr., Schwein, A., Shabashvili, A.E., Hauswirth, W.W., Gorbatyuk, M.S., Lewin, A.S., AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum. Gene Ther. 22 (2011), 567–575.
163. Marc, R.E., Jones, B.W., Watt, C.B., Strettoi, E., Neural remodeling in retinal degeneration. Prog. Retin Eye Res. 22 (2003), 607–655.
164. Massof, R.W., Fishman, G.A., How strong is the evidence that nutritional supplements slow the progression of retinitis pigmentosa?. Arch. Ophthalmol. 128 (2010), 493–495.
165. Mathieson, K., Loudin, J., Goetz, G., Huie, P., Wang, L., Kamins, T.I., Galambos, L., Smith, R., Harris, J.S., Sher, A., Palanker, D., Photovoltaic retinal prosthesis with high pixel density. Nat. Photonics 6 (2012), 391–397.
166. Maubaret, C.G., Vaclavik, V., Mukhopadhyay, R., Waseem, N.H., Churchill, A., Holder, G.E., Moore, A.T., Bhattacharya, S.S., Webster, A.R., Autosomal dominant retinitis pigmentosa with intrafamilial variability and incomplete penetrance in two families carrying mutations in PRPF8. Invest Ophthalmol. Vis. Sci. 52 (2011), 9304–9309.
167. Mead, B., Berry, M., Logan, A., Scott, R.A., Leadbeater, W., Scheven, B.A., Stem cell treatment of degenerative eye disease. Stem Cell Res. 14 (2015), 243–257.
168. Mendes, H.F., van der Spuy, J., Chapple, J.P., Cheetham, M.E., Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol. Med. 11 (2005), 177–185.
169. Millington-Ward, S., Chadderton, N., O'Reilly, M., Palfi, A., Goldmann, T., Kilty, C., Humphries, M., Wolfrum, U., Bennett, J., Humphries, P., Kenna, P.F., Farrar, G.J., Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol. Ther. 19 (2011), 642–649.
170. Miranda, M., Arnal, E., Ahuja, S., Alvarez-Nolting, R., Lopez-Pedrajas, R., Ekstrom, P., Bosch-Morell, F., van Veen, T., Romero, F.J., Antioxidants rescue photoreceptors in rd1 mice: relationship with thiol metabolism. Free Radic. Biol. Med. 48 (2010), 216–222.
171. Miyoshi, H., Takahashi, M., Gage, F.H., Verma, I.M., Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 10319–10323.
172. Morimura, H., Fishman, G.A., Grover, S.A., Fulton, A.B., Berson, E.L., Dryja, T.P., Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 3088–3093.
173. Moustafa, G.A., Moschos, M.M., Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature. BMC Ophthalmol., 15, 2015, 44.
174. Murakami, Y., Notomi, S., Hisatomi, T., Nakazawa, T., Ishibashi, T., Miller, J.W., Vavvas, D.G., Photoreceptor cell death and rescue in retinal detachment and degenerations. Prog. Retin. Eye Res. 37 (2013), 114–140.
175. Murase, H., Tsuruma, K., Shimazawa, M., Hara, H., TUDCA promotes phagocytosis by retinal pigment epithelium via MerTK activation. Invest Ophthalmol. Vis. Sci. 56 (2015), 2511–2518.
176. Na, K.H., Kim, H.J., Kim, K.H., Han, S., Kim, P., Hann, H.J., Ahn, H.S., Prevalence, age at diagnosis, mortality, and cause of death in retinitis pigmentosa in Korea-a nationwide population-based study. Am. J. Ophthalmol. 176 (2017), 157–165.
177. Nakazawa, M., Ohguro, H., Takeuchi, K., Miyagawa, Y., Ito, T., Metoki, T., Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. Ophthalmologica 225 (2011), 120–126.
178. Nakazawa, M., Suzuki, Y., Ito, T., Metoki, T., Kudo, T., Ohguro, H., Long-term effects of nilvadipine against progression of the central visual field defect in retinitis pigmentosa: an extended study. Biomed. Res. Int., 2013, 2013, 585729.
179. Nash, B.M., Wright, D.C., Grigg, J.R., Bennetts, B., Jamieson, R.V., Retinal dystrophies, genomic applications in diagnosis and prospects for therapy. Transl. Pediatr. 4 (2015), 139–163.
180. Nilsson, S.E., Wrigstad, A., Narfstrom, K., Changes in the DC electroretinogram in Briard dogs with hereditary congenital night blindness and partial day blindness. Exp. Eye Res. 54 (1992), 291–296.
181. O'Reilly, M., Millington-Ward, S., Palfi, A., Chadderton, N., Cronin, T., McNally, N., Humphries, M.M., Humphries, P., Kenna, P.F., Farrar, G.J., A transgenic mouse model for gene therapy of rhodopsin-linked Retinitis Pigmentosa. Vis. Res. 48 (2008), 386–391.
182. Ochoa, G.P., Sesma, J.Z., Diez, M.A., Diaz-Tahoces, A., Aviles-Trigeros, M., Grijalvo, S., Eritja, R., Fernandez, E., Pedraz, J.L., A novel formulation based on 2,3-di(tetradecyloxy)propan-1-amine cationic lipid combined with polysorbate 80 for efficient gene delivery to the retina. Pharm. Res. 31 (2014), 1665–1675.
183. Oishi, M., Oishi, A., Gotoh, N., Ogino, K., Higasa, K., Iida, K., Makiyama, Y., Morooka, S., Matsuda, F., Yoshimura, N., Comprehensive molecular diagnosis of a large cohort of Japanese retinitis pigmentosa and Usher syndrome patients by next-generation sequencing. Invest Ophthalmol. Vis. Sci. 55 (2014), 7369–7375.
184. Ozaki, T., Nakazawa, M., Kudo, T., Hirano, S., Suzuki, K., Ishiguro, S., Protection of cone photoreceptor M-opsin degradation with 9-cis-beta-carotene-rich alga Dunaliella bardawil in Rpe65(-/-) mouse retinal explant culture. Curr. Eye Res. 39 (2014), 1221–1231.
185. Palczewski, K., G protein-coupled receptor rhodopsin. Annu. Rev. Biochem. 75 (2006), 743–767.
186. Pang, J., Cheng, M., Stevenson, D., Trousdale, M.D., Dorey, C.K., Blanks, J.C., Adenoviral-mediated gene transfer to retinal explants during development and degeneration. Exp. Eye Res. 79 (2004), 189–201.
187. Pang, J.J., Chang, B., Hawes, N.L., Hurd, R.E., Davisson, M.T., Li, J., Noorwez, S.M., Malhotra, R., McDowell, J.H., Kaushal, S., Hauswirth, W.W., Nusinowitz, S., Thompson, D.A., Heckenlively, J.R., Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). Mol. Vis. 11 (2005), 152–162.
188. Paquet-Durand, F., Sanges, D., McCall, J., Silva, J., van Veen, T., Marigo, V., Ekstrom, P., Photoreceptor rescue and toxicity induced by different calpain inhibitors. J. Neurochem. 115 (2010), 930–940.
189. Park, S.J., Choi, Y., Na, Y.M., Hong, H.K., Park, J.Y., Park, K.H., Chung, J.Y., Woo, S.J., Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a Rabbit model. Invest Ophthalmol. Vis. Sci. 57 (2016), 2612–2617.
190. Park, S.S., Bauer, G., Abedi, M., Pontow, S., Panorgias, A., Jonnal, R., Zawadzki, R.J., Werner, J.S., Nolta, J., Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol. Vis. Sci. 56 (2014), 81–89.
191. Park, T.K., Wu, Z., Kjellstrom, S., Zeng, Y., Bush, R.A., Sieving, P.A., Colosi, P., Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther. 16 (2009), 916–926.
192. Pawlyk, B.S., Bulgakov, O.V., Sun, X., Adamian, M., Shu, X., Smith, A.J., Berson, E.L., Ali, R.R., Khani, S., Wright, A.F., Sandberg, M.A., Li, T., Photoreceptor rescue by an abbreviated human RPGR gene in a murine model of X-linked retinitis pigmentosa. Gene Ther. 23 (2016), 196–204.
193. Pawlyk, B.S., Li, T., Scimeca, M.S., Sandberg, M.A., Berson, E.L., Absence of photoreceptor rescue with D-cis-diltiazem in the rd mouse. Invest Ophthalmol. Vis. Sci. 43 (2002), 1912–1915.
194. Pearce-Kelling, S.E., Aleman, T.S., Nickle, A., Laties, A.M., Aguirre, G.D., Jacobson, S.G., Acland, G.M., Calcium channel blocker D-cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis pigmentosa. Mol. Vis. 7 (2001), 42–47.
195. Pearring, J.N., Salinas, R.Y., Baker, S.A., Arshavsky, V.Y., Protein sorting, targeting and trafficking in photoreceptor cells. Prog. Retin Eye Res. 36 (2013), 24–51.
196. Pensado, A., Diaz-Corrales, F.J., De la Cerda, B., Valdes-Sanchez, L., Del Boz, A.A., Rodriguez-Martinez, D., Garcia-Delgado, A.B., Seijo, B., Bhattacharya, S.S., Sanchez, A., Span poly-L-arginine nanoparticles are efficient non-viral vectors for PRPF31 gene delivery: an approach of gene therapy to treat retinitis pigmentosa. Nanomedicine 12 (2016), 2251–2260.
197. Perez, M., Rojo, A.I., Wandosell, F., Diaz-Nido, J., Avila, J., Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem. J. 372 (2003), 129–136.
198. Petoe, M.A., McCarthy, C.D., Shivdasani, M.N., Sinclair, N.C., Scott, A.F., Ayton, L.N., Barnes, N.M., Guymer, R.H., Allen, P.J., Blamey, P.J., Bionic vision Australia, C. Determining the Contribution of Retinotopic Discrimination to Localization Performance With a Suprachoroidal Retinal Prosthesis. Invest Ophthalmol. Vis. Sci. 58 (2017), 3231–3239.
199. Petrs-Silva, H., Linden, R., Advances in gene therapy technologies to treat retinitis pigmentosa. Clin. Ophthalmol. 8 (2014), 127–136.
200. Piano, I., Novelli, E., Gasco, P., Ghidoni, R., Strettoi, E., Gargini, C., Cone survival and preservation of visual acuity in an animal model of retinal degeneration. Eur. J. Neurosci. 37 (2013), 1853–1862.
201. Qi, Y., Dai, X., Zhang, H., He, Y., Zhang, Y., Han, J., Zhu, P., Zhang, Y., Zheng, Q., Li, X., Zhao, C., Pang, J., Trans-corneal subretinal injection in mice and its effect on the function and morphology of the retina. PLoS One, 10, 2015, e0136523.
202. Rajala, A., Wang, Y., Zhu, Y., Ranjo-Bishop, M., Ma, J.X., Mao, C., Rajala, R.V., Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo. Nano Lett. 14 (2014), 5257–5263.
203. Rasheva, V.I., Domingos, P.M., Cellular responses to endoplasmic reticulum stress and apoptosis. Apoptosis 14 (2009), 996–1007.
204. Reuter, J.H., Sanyal, S., Development and degeneration of retina in rds mutant mice: the electroretinogram. Neurosci. Lett. 48 (1984), 231–237.
205. Rizzo, J.F. 3rd, Update on retinal prosthetic research: the boston retinal implant project. J. Neuroophthalmol. 31 (2011), 160–168.
206. Rizzo, J.F. 3rd, Wyatt, J., Loewenstein, J., Kelly, S., Shire, D., Perceptual efficacy of electrical stimulation of human retina with a microelectrode array during short-term surgical trials. Invest Ophthalmol. Vis. Sci. 44 (2003), 5362–5369.
207. Roessler, G., Laube, T., Brockmann, C., Kirschkamp, T., Mazinani, B., Goertz, M., Koch, C., Krisch, I., Sellhaus, B., Trieu, H.K., Weis, J., Bornfeld, N., Rothgen, H., Messner, A., Mokwa, W., Walter, P., Implantation and explantation of a wireless epiretinal retina implant device: observations during the EPIRET3 prospective clinical trial. Invest Ophthalmol. Vis. Sci. 50 (2009), 3003–3008.
208. Rohrer, B., Goletz, P., Znoiko, S., Ablonczy, Z., Ma, J.X., Redmond, T.M., Crouch, R.K., Correlation of regenerable opsin with rod ERG signal in Rpe65-/- mice during development and aging. Invest Ophthalmol. Vis. Sci. 44 (2003), 310–315.
209. Rossmiller, B., Mao, H., Lewin, A.S., Gene therapy in animal models of autosomal dominant retinitis pigmentosa. Mol. Vis. 18 (2012), 2479–2496.
210. Russell, S., Bennett, J., Wellman, J.A., Chung, D.C., Yu, Z.F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., Cross, D., Marshall, K.A., Walshire, J., Kehoe, T.L., Reichert, H., Davis, M., Raffini, L., George, L.A., Hudson, F.P., Dingfield, L., Zhu, X., Haller, J.A., Sohn, E.H., Mahajan, V.B., Pfeifer, W., Weckmann, M., Johnson, C., Gewaily, D., Drack, A., Stone, E., Wachtel, K., Simonelli, F., Leroy, B.P., Wright, J.F., High, K.A., Maguire, A.M., Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390 (2017), 849–860.
211. Sacchetti, M., Mantelli, F., Merlo, D., Lambiase, A., Systematic review of randomized clinical trials on safety and efficacy of pharmacological and nonpharmacological treatments for retinitis pigmentosa. J. Ophthalmol., 2015, 2015, 737053.
212. Sahel, J.A., Roska, B., Gene therapy for blindness. Annu. Rev. Neurosci. 36 (2013), 467–488.
213. Sahni, J.N., Angi, M., Irigoyen, C., Semeraro, F., Romano, M.R., Parmeggiani, F., Therapeutic challenges to retinitis pigmentosa: from neuroprotection to gene therapy. Curr. Genomics 12 (2011), 276–284.
214. Salom, D., Diaz-Llopis, M., Garcia-Delpech, S., Udaondo, P., Romero, F.J., Millan, J.M., Arevalo, J.F., Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa. J. Ocul. Pharmacol. Ther. 26 (2010), 531–532.
215. Sanchez-Vallejo, V., Benlloch-Navarro, S., Lopez-Pedrajas, R., Romero, F.J., Miranda, M., Neuroprotective actions of progesterone in an in vivo model of retinitis pigmentosa. Pharmacol. Res. 99 (2015), 276–288.
216. Sandberg, M.A., Rosner, B., Weigel-DiFranco, C., Berson, E.L., Lack of scientific rationale for use of valproic acid for retinitis pigmentosa. Br. J. Ophthalmol., 95, 2011, 744.
217. Schwartz, S.D., Regillo, C.D., Lam, B.L., Eliott, D., Rosenfeld, P.J., Gregori, N.Z., Hubschman, J.P., Davis, J.L., Heilwell, G., Spirn, M., Maguire, J., Gay, R., Bateman, J., Ostrick, R.M., Morris, D., Vincent, M., Anglade, E., Del Priore, L.V., Lanza, R., Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385 (2015), 509–516.
218. Scott, P.A., Kaplan, H.J., McCall, M.A., Prenatal exposure to curcumin protects rod photoreceptors in a transgenic Pro23His swine model of retinitis pigmentosa. Transl. Vis. Sci. Technol., 4, 2015, 5.
219. Seiler, M.J., Aramant, R.B., Cell replacement and visual restoration by retinal sheet transplants. Prog. Retin Eye Res. 31 (2012), 661–687.
220. Shanmugam, P.M., Minija, C.K., Ramanjulu, R., Tekwani, P., Saxena, M., Effect of short-term oral valproic Acid on vision and visual field in retinitis pigmentosa. Ophthalmol. Ther., 1, 2012, 6.
221. Sheu, S.J., Bee, Y.S., Chen, C.H., Resveratrol and large-conductance calcium-activated potassium channels in the protection of human retinal pigment epithelial cells. J. Ocul. Pharmacol. Ther. 24 (2008), 551–555.
222. Shintani, K., Shechtman, D.L., Gurwood, A.S., Review and update: current treatment trends for patients with retinitis pigmentosa. Optometry 80 (2009), 384–401.
223. Shirai, H., Mandai, M., Matsushita, K., Kuwahara, A., Yonemura, S., Nakano, T., Assawachananont, J., Kimura, T., Saito, K., Terasaki, H., Eiraku, M., Sasai, Y., Takahashi, M., Transplantation of human embryonic stem cell-derived retinal tissue in two primate models of retinal degeneration. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E81–E90.
224. Sieving, P.A., Caruso, R.C., Tao, W., Coleman, H.R., Thompson, D.J., Fullmer, K.R., Bush, R.A., Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 3896–3901.
225. Siqueira, R.C., Messias, A., Messias, K., Arcieri, R.S., Ruiz, M.A., Souza, N.F., Martins, L.C., Jorge, R., Quality of life in patients with retinitis pigmentosa submitted to intravitreal use of bone marrow-derived stem cells (Reticell -clinical trial). Stem Cell Res. Ther., 6, 2015, 29.
226. Siqueira, R.C., Messias, A., Voltarelli, J.C., Scott, I.U., Jorge, R., Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial. Retina 31 (2011), 1207–1214.
227. Sisk, R.A., Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa. Br. J. Ophthalmol. 96 (2012), 1154–1155.
228. Slijkerman, R.W., Song, F., Astuti, G.D., Huynen, M.A., van Wijk, E., Stieger, K., Collin, R.W., The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies. Prog. Retin Eye Res. 48 (2015), 137–159.
229. Smith, A.J., Schlichtenbrede, F.C., Tschernutter, M., Bainbridge, J.W., Thrasher, A.J., Ali, R.R., AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol. Ther. 8 (2003), 188–195.
230. Stingl, K., Bartz-Schmidt, K.U., Besch, D., Chee, C.K., Cottriall, C.L., Gekeler, F., Groppe, M., Jackson, T.L., MacLaren, R.E., Koitschev, A., Kusnyerik, A., Neffendorf, J., Nemeth, J., Naeem, M.A., Peters, T., Ramsden, J.D., Sachs, H., Simpson, A., Singh, M.S., Wilhelm, B., Wong, D., Zrenner, E., Subretinal visual implant alpha IMS–clinical trial interim report. Vis. Res. 111 (2015), 149–160.
231. Strettoi, E., Gargini, C., Novelli, E., Sala, G., Piano, I., Gasco, P., Ghidoni, R., Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 18706–18711.
232. Stuck, M.W., Conley, S.M., Naash, M.I., PRPH2/RDS and ROM-1: historical context, current views and future considerations. Prog. Retin Eye Res. 52 (2016), 47–63.
233. Tee, J.J., Smith, A.J., Hardcastle, A.J., Michaelides, M., RPGR-associated retinopathy: clinical features, molecular genetics, animal models and therapeutic options. Br. J. Ophthalmol. 100 (2016), 1022–1027.
234. Thomson, L.R., Toyoda, Y., Langner, A., Delori, F.C., Garnett, K.M., Craft, N., Nichols, C.R., Cheng, K.M., Dorey, C.K., Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. Invest Ophthalmol. Vis. Sci. 43 (2002), 3538–3549.
235. Trapani, I., Puppo, A., Auricchio, A., Vector platforms for gene therapy of inherited retinopathies. Prog. Retin Eye Res. 43 (2014), 108–128.
236. Trifunovic, D., Sahaboglu, A., Kaur, J., Mencl, S., Zrenner, E., Ueffing, M., Arango-Gonzalez, B., Paquet-Durand, F., Neuroprotective strategies for the treatment of inherited photoreceptor degeneration. Curr. Mol. Med. 12 (2012), 598–612.
237. Tschernutter, M., Schlichtenbrede, F.C., Howe, S., Balaggan, K.S., Munro, P.M., Bainbridge, J.W., Thrasher, A.J., Smith, A.J., Ali, R.R., Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. Gene Ther. 12 (2005), 694–701.
238. Tso, M.O., Zhang, C., Abler, A.S., Chang, C.J., Wong, F., Chang, G.Q., Lam, T.T., Apoptosis leads to photoreceptor degeneration in inherited retinal dystrophy of RCS rats. Invest Ophthalmol. Vis. Sci. 35 (1994), 2693–2699.
239. Tsuruma, K., Tanaka, Y., Shimazawa, M., Mashima, Y., Hara, H., Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction, by activating BK channels. Mol. Vis. 17 (2011), 3556–3565.
240. Tucker, B.A., Park, I.H., Qi, S.D., Klassen, H.J., Jiang, C., Yao, J., Redenti, S., Daley, G.Q., Young, M.J., Transplantation of adult mouse iPS cell-derived photoreceptor precursors restores retinal structure and function in degenerative mice. PLoS One, 6, 2011, e18992.
241. Vacca, O., Darche, M., Schaffer, D.V., Flannery, J.G., Sahel, J.A., Rendon, A., Dalkara, D., AAV-mediated gene delivery in Dp71-null mouse model with compromised barriers. Glia 62 (2014), 468–476.
242. van Soest, S., Westerveld, A., de Jong, P.T., Bleeker-Wagemakers, E.M., Bergen, A.A., Retinitis pigmentosa: defined from a molecular point of view. Surv. Ophthalmol. 43 (1999), 321–334.
243. Vasireddy, V., Chavali, V.R., Joseph, V.T., Kadam, R., Lin, J.H., Jamison, J.A., Kompella, U.B., Reddy, G.B., Ayyagari, R., Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation. PLoS One, 6, 2011, e21193.
244. Veleri, S., Lazar, C.H., Chang, B., Sieving, P.A., Banin, E., Swaroop, A., Biology and therapy of inherited retinal degenerative disease: insights from mouse models. Dis. Model Mech. 8 (2015), 109–129.
245. Vinores, S.A., Kuchle, M., Derevjanik, N.L., Henderer, J.D., Mahlow, J., Green, W.R., Campochiaro, P.A., Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization. Histol. Histopathol. 10 (1995), 913–923.
246. Vithana, E.N., Abu-Safieh, L., Pelosini, L., Winchester, E., Hornan, D., Bird, A.C., Hunt, D.M., Bustin, S.A., Bhattacharya, S.S., Expression of PRPF31 mRNA in patients with autosomal dominant retinitis pigmentosa: a molecular clue for incomplete penetrance?. Invest Ophthalmol. Vis. Sci. 44 (2003), 4204–4209.
247. Vollrath, D., Feng, W., Duncan, J.L., Yasumura, D., D'Cruz, P.M., Chappelow, A., Matthes, M.T., Kay, M.A., LaVail, M.M., Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 12584–12589.
248. Wan, X., Pei, H., Zhao, M.J., Yang, S., Hu, W.K., He, H., Ma, S.Q., Zhang, G., Dong, X.Y., Chen, C., Wang, D.W., Li, B., Efficacy and safety of rAAV2-ND4 treatment for Leber's hereditary optic neuropathy. Sci. Rep., 6, 2016, 21587.
249. Wang, K., Xiao, J., Peng, B., Xing, F., So, K.F., Tipoe, G.L., Lin, B., Retinal structure and function preservation by polysaccharides of wolfberry in a mouse model of retinal degeneration. Sci. Rep., 4, 2014, 7601.
250. Waseem, N.H., Vaclavik, V., Webster, A., Jenkins, S.A., Bird, A.C., Bhattacharya, S.S., Mutations in the gene coding for the pre-mRNA splicing factor, PRPF31, in patients with autosomal dominant retinitis pigmentosa. Invest Ophthalmol. Vis. Sci. 48 (2007), 1330–1334.
251. Watanabe, M., Fukuda, Y., Survival and axonal regeneration of retinal ganglion cells in adult cats. Prog. Retin Eye Res. 21 (2002), 529–553.
252. Waters, A.M., Beales, P.L., Ciliopathies: an expanding disease spectrum. Pediatr. Nephrol. 26 (2011), 1039–1056.
253. Weber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot, D., Cherel, Y., Chenuaud, P., Samulski, J., Moullier, P., Rolling, F., Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol. Ther. 7 (2003), 774–781.
254. Weiland, J.D., Humayun, M.S., Retinal prosthesis. IEEE Trans. Biomed. Eng. 61 (2014), 1412–1424.
255. Wheway, G., Parry, D.A., Johnson, C.A., The role of primary cilia in the development and disease of the retina. Organogenesis 10 (2014), 69–85.
256. Will, C.L., Luhrmann, R., Spliceosome structure and function. Cold Spring Harb. Perspect. Biol., 3, 2011.
257. Yamamoto, S., Sugawara, T., Murakami, A., Nakazawa, M., Nao, I.N., Machida, S., Wada, Y., Mashima, Y., Myake, Y., Topical isopropyl unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical study. Ophthalmol. Ther., 1, 2012, 5.
258. Yanai, D., Weiland, J.D., Mahadevappa, M., Greenberg, R.J., Fine, I., Humayun, M.S., Visual performance using a retinal prosthesis in three subjects with retinitis pigmentosa. Am. J. Ophthalmol. 143 (2007), 820–827.
259. Yanik, M., Muller, B., Song, F., Gall, J., Wagner, F., Wende, W., Lorenz, B., Stieger, K., In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies. Prog. Retin Eye Res. 56 (2017), 1–18.
260. Yasuda, S., Liang, M.H., Marinova, Z., Yahyavi, A., Chuang, D.M., The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 14 (2009), 51–59.
261. Yoshida, N., Ikeda, Y., Notomi, S., Ishikawa, K., Murakami, Y., Hisatomi, T., Enaida, H., Ishibashi, T., Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 120 (2013), 100–105.
262. Yoshida, N., Ikeda, Y., Notomi, S., Ishikawa, K., Murakami, Y., Hisatomi, T., Enaida, H., Ishibashi, T., Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 120 (2013), e5–12.
263. Yuan, L., Kawada, M., Havlioglu, N., Tang, H., Wu, J.Y., Mutations in PRPF31 inhibit pre-mRNA splicing of rhodopsin gene and cause apoptosis of retinal cells. J. Neurosci. 25 (2005), 748–757.
264. Yue, L., Falabella, P., Christopher, P., Wuyyuru, V., Dorn, J., Schor, P., Greenberg, R.J., Weiland, J.D., Humayun, M.S., Ten-year follow-up of a blind patient Chronically implanted with epiretinal prosthesis Argus I. Ophthalmology 122 (2015), 2545–2552 e2541.
265. Yue, L., Weiland, J.D., Roska, B., Humayun, M.S., Retinal stimulation strategies to restore vision: fundamentals and systems. Prog. Retin Eye Res. 53 (2016), 21–47.
266. Yuzbasioglu, E., Artunay, O., Rasier, R., Sengul, A., Bahcecioglu, H., Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa. Curr. Eye Res. 34 (2009), 231–237.
267. Zhao, C., Bellur, D.L., Lu, S., Zhao, F., Grassi, M.A., Bowne, S.J., Sullivan, L.S., Daiger, S.P., Chen, L.J., Pang, C.P., Zhao, K., Staley, J.P., Larsson, C., Autosomal-dominant retinitis pigmentosa caused by a mutation in SNRNP200, a gene required for unwinding of U4/U6 snRNAs. Am. J. Hum. Genet. 85 (2009), 617–627.
268. Zheng, A., Li, Y., Tsang, S.H., Personalized therapeutic strategies for patients with retinitis pigmentosa. Expert Opin. Biol. Ther. 15 (2015), 391–402.
269. Zhou, L., Wang, W., Liu, Y., Fernandez de Castro, J., Ezashi, T., Telugu, B.P., Roberts, R.M., Kaplan, H.J., Dean, D.C., Differentiation of induced pluripotent stem cells of swine into rod photoreceptors and their integration into the retina. Stem Cells 29 (2011), 972–980.
270. Zulliger, R., Conley, S.M., Naash, M.I., Non-viral therapeutic approaches to ocular diseases: an overview and future directions. J. Control Release 219 (2015), 471–487.